[go: up one dir, main page]

WO2008107699A1 - Diagnostic de troubles psychotiques - Google Patents

Diagnostic de troubles psychotiques Download PDF

Info

Publication number
WO2008107699A1
WO2008107699A1 PCT/GB2008/000826 GB2008000826W WO2008107699A1 WO 2008107699 A1 WO2008107699 A1 WO 2008107699A1 GB 2008000826 W GB2008000826 W GB 2008000826W WO 2008107699 A1 WO2008107699 A1 WO 2008107699A1
Authority
WO
WIPO (PCT)
Prior art keywords
biomarker
sample
subject
quantifying
detecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/000826
Other languages
English (en)
Inventor
Sabine Bahn
Rachel Marie Craddock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0704513A external-priority patent/GB0704513D0/en
Priority claimed from GB0720545A external-priority patent/GB0720545D0/en
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of WO2008107699A1 publication Critical patent/WO2008107699A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70589—CD45
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Definitions

  • the invention relates to methods for diagnosing or monitoring psychotic disorders, in particular schizophrenic disorders, using biomarkers.
  • Psychosis is a symptom of severe mental illness. Although it is not exclusively linked to any particular psychological or physical state, it is particularly associated with schizophrenia, bipolar disorder (manic depression) and severe clinical depression. These conditions, their characterisation and categorisation, including DSM IV diagnosis criteria, are described in WO2007/045865, the content of which is incorporated herein by reference.
  • WO01 /63295 describes methods and compositions for screening, diagnosis and determining prognosis of neuropsychiatric or neurological conditions (including bipolar affective disorder, schizophrenia and vascular dementia), for monitoring the effectiveness of treatment in these conditions and for use in drug development.
  • biomarkers Used as predictors, these biomarkers can help to identify high-risk individuals and disease sub-groups that may serve as target populations for chemo-intervention trials; as surrogate endpoints, biomarkers have the potential for assessing the efficacy and cost effectiveness of preventative interventions at a speed which is not possible at present when the incidence of manifest mental disorder is used as the endpoint.
  • WO2005/020784 discloses surrogate cell gene expression signatures, by a minimally invasive technique for determining the prognosis of a subject or the subjects susceptibility to a disease, disorder or physical state. It is reported (in Example 2) that various genes are modulated in, inter alia, psychiatric illness.
  • T-cells are lymphocytes which develop in the thymus and play an important role in the immune system. There are two sub-populations of T-cells: cells with a CD4 marker are called helper T-cells whilst CD8+ cells are cytotoxic T-cells. Both T- cell types have a T-cell receptor (TCR) for antigen recognition. Stimulation or activation of a resting T-cell is initiated by the interaction of the TCR-CD3 complex with antigen-MHC class Il molecules on the surface of an antigen-presenting cell. This interaction initiates a cascade of biochemical events in the T-cell, including activation of gene transcription that eventually results in growth, proliferation and differentiation of the T-cell.
  • TCR T-cell receptor
  • WO2007/063333 discloses that assays, conducted on stimulated or unstimulated T-cells, can provide valuable information on the condition of a subject.
  • T-cells provide a good model in which to investigate cellular function, as they are relatively easy to isolate with high purity, e.g. from peripheral blood, and can be obtained in a minimally invasive fashion.
  • the present invention is based on the Study, below. This shows that schizophrenia patients have a higher number of na ⁇ ve T-cells, by expression of CD45RA and CD45RB at least.
  • An aspect of this invention is a method of diagnosing, predicting or monitoring a psychotic disorder in a subject by assessing the level of circulating naive T-cells and/or their expression of CD45, e.g. one or more of CD45RA, CD45RB and CD45RO.
  • the T-cells are preferably stimulated. Description of Preferred Embodiments
  • diagnosis encompasses identification, confirmation, and/or characterisation of a psychotic disorder, in particular a schizophrenic disorder, bipolar disorder, related psychotic disorder, or predisposition thereto.
  • predisposition it is meant that a subject does not currently present with the disorder, but is liable to be affected by the disorder in time.
  • Monitoring methods of the invention can be used to monitor onset, progression, stabilisation, amelioration and/or remission of a psychotic disorder.
  • psychotic disorder refers to a disorder in which psychosis is a recognised symptom, this includes neuropsychiatric (psychotic depression and other psychotic episodes) and neurodevelopmental disorders (especially autistic spectrum disorders), neurodegenerative disorders, depression, mania, and in particular, schizophrenic disorders (paranoid, catatonic, disorganized, undifferentiated and residual schizophrenia) and bipolar disorders.
  • the invention relates to schizophrenic disorders.
  • T-cell samples are preferably obtained from peripheral blood taken from a subject.
  • T-cell samples are freshly isolated, that is they are used immediately following sample collection.
  • T-cell isolation An example of a method for T-cell isolation is described in Example 1 of WO2007/063333.
  • a biological sample such as peripheral blood
  • T-cell stimulation refers to a stimulus capable of inducing a response, preferably T-cell proliferation and responses associated with T-cell receptor-triggering.
  • T-cell stimulation may be used as a method of comparing the functional responses of patient and control cells, firstly in order to investigate peripheral evidence of disease processes in schizophrenia and also to investigate whether global abnormalities or deficits in cell processes, such as cell signalling, gene transcription, protein synthesis and trafficking underlie the pathophysiology of this disorder.
  • T-cell activation involves ligation of the T-cell receptor (TCR) through interaction with specific antigen presented in association with MHC.
  • the TCR signalling complex is composed of a number of molecules including CD3, which provides the cytoplasmic signalling function of the complex, CD45, involved in de- phosphorylation of inhibitory phosphorylated tyrosine motifs and either CD4 or CD8, which are believed to stabilise the signalling complex.
  • CD3 which provides the cytoplasmic signalling function of the complex
  • CD45 involved in de- phosphorylation of inhibitory phosphorylated tyrosine motifs and either CD4 or CD8, which are believed to stabilise the signalling complex.
  • co-stimulation is preferred for amplification and regulation of the initial signal. This is provided by molecules such as CD28, CD40, CD80/CD86 and OX40L.
  • stimulation of T-cells is carried out in vitro by mimicking a TCR signal via cross-linking of cell surface CD3, using a monoclonal antibody (anti-CD3).
  • anti-CD3 a monoclonal antibody
  • methods of the invention aim to identify and trace any abnormalities in these physiological processes and any consequences (e.g. differences in response to stimulus which may manifest in differences in mRNA, protein, lipid or other metabolite levels or ratios associated with such abnormalities).
  • the stimulus is anti-CD3 antibody.
  • Stimulation of T-cells may also be carried out using other agents, for example ionomycin and PMA, alone or in combination with CD3.
  • response may thus refer to a response elicited in response to the stimulation/activation of a resting T-cell.
  • responses include proliferation, transcription factor activation or deactivation and modulation of one or more of the following: gene expression, protein synthesis, signal transduction, cytokine synthesis, protein trafficking and protein turnover, metabolite or lipid profile.
  • the response comprises proliferation, modulation of gene expression, protein synthesis and/or protein turnover.
  • Methods of the invention may comprise comparing a response in a test T-cell sample from a subject with a response to stimulation in a control.
  • Suitable controls include normal controls derived from individuals not unaffected by or predisposed to psychotic disorder and disorder controls derived from individuals with a psychotic disorder preferably a schizophrenic disorder.
  • Methods of the invention may comprise detecting a difference in a response between the test sample and a control sample.
  • methods of the invention may involve comparing a response in a test T- cell sample with a response in a normal control T-cell sample, wherein a difference in response is indicative of the presence of or predisposition to a psychotic disorder such as a schizophrenic disorder. Differences in response may be detected as a presence, absence, increase or decrease in a particular response to stimulus.
  • methods of the invention may comprise a response in a test T-cell sample with a response in a psychotic disorder control T-cell sample, to enable the test T-cell response to be matched to the response characteristic of a particular psychotic disorder; such comparisons are useful for differential diagnosis of psychotic disorders that present with similar or overlapping clinical symptoms.
  • T-cells from schizophrenia patients have been found to have significantly lower proliferation compared to healthy controls, as illustrated in Example 2 of WO2007/063333.
  • a lower proliferation in a T-cell sample from a subject compared to proliferation in a normal control T-cell sample is indicative of a psychotic disorder, in particular schizophrenia, being present.
  • Proliferation may be assessed by 3 [H]- thymidine incorporation into progeny cell DNA, as illustrated in Example 1 of WO2007/063333.
  • Differences in responses of T-cells from individuals having or predisposed to psychotic disorders and those from normal individuals may also be detected by assessing modulation in gene expression in response to exposure to stimulus, preferably in response to exposure to a stimulus for T-cell proliferation. Differences in responses may also be assessed by considering the downstream effects of differential gene expression in subjects having or being predisposed to a psychotic disorder, e.g. differences in metabolic profile, lipid profile, or differences in levels or ratio of biomarkers, compared to those in normal individuals not suffering from or predisposed to a psychotic disorder.
  • modulated and modulation are used herein to mean an upregulation or downregulation of expression of a gene or differences in the proteome, for example, an increase or decrease in protein level. Modulation of gene expression can be measured by detecting a variation in mRNA or protein levels. The increase or decrease in protein level may be assessed by simply determining the presence or absence of a protein or by using a quantitative method.
  • modulation of expression can be identified by assessing the amount or concentration of mRNA, a nucleic acid derived from mRNA or a protein translated from the mRNA.
  • Gene expression may be measured by assessing mRNA levels using a method including reverse transcription and polymerase chain reactions ("RT-PCR"), such as quantitative PCR (in particular, real-time quantitative PCR), and Northern blotting.
  • RT-PCR reverse transcription and polymerase chain reactions
  • RNA sample is obtained from the cell, cDNA is synthesized from mRNA of the gene or genes of interest, and the cDNA is used for real-time quantitative PCR analysis to determine the level of the mRNA of interest in the sample.
  • Systems and kits for implementing such methods are commercially available.
  • Arrays may be used to assess expression of a plurality of genes or proteins, for example using weak cation exchange (CM10) chips for SELDI analysis of proteins, or Codelink Bioarrays for gene expression.
  • CM10 weak cation exchange
  • An example of a method used to assess gene expression is shown in Example 3 of WO2007/063333.
  • suitable methods for determining the level of protein expression or identifying protein biomarkers include immunological methods, involving an antibody, or an antibody fragment capable of specific binding to the protein of interest.
  • Suitable immunological methods include sandwich immunoassays, such as sandwich ELISA in which detection of the peptide is performed using two antibodies which recognize different epitopes; radioimmunoassays (RIA), direct or competitive enzyme-linked immunosorbent assays (ELISA), enzyme-immuno assays (EIA), Western blotting, immunoprecipitation and any particle-based immunoassay (e.g. using gold, silver, latex or magnetic particles or Q-dots). Immunological methods may be performed, for example, in microtitre plate or strip format.
  • sandwich immunoassays such as sandwich ELISA in which detection of the peptide is performed using two antibodies which recognize different epitopes
  • RIA radioimmunoassays
  • ELISA direct or competitive enzyme-linked immunosorbent assays
  • EIA enzyme-immuno assays
  • Western blotting immunoprecipitation and any particle-based immunoassay (e.g. using gold, silver, latex
  • spectral analysis such as NMR spectroscopy and high resolution NMR spectroscopy ( 1 H NMR)
  • mass spectrometry such as Surface Enhanced Laser/Desorption Ionization (SELDI) (-TOF) and/or MALDI (-TOF)
  • 1-D gel-based analysis 2-D gel- based analysis
  • LC-MS-based technique iTRAQTM.
  • iTRAQTM technology involves the chemical tagging of N-terminus peptides resulting from protein digestion with trypsin. Up to four labelled samples are combined, fractionated by nano-LC and analysed by tandem mass spectrometry. Protein identification is then achieved by database searching of fragmentation data. Relative quantification of peptides is achieved by fragmentation of the chemical tag, which results in a low molecular weight reporter ion. As samples are labelled after tryptic digestion, analysis of high molecular weight proteins such as trans-membrane receptors is possible and quantification of fragmented tag provides greater confidence in protein identity and quantification.
  • a suitable cohort of patients and controls may be selected including first onset and/or minimally treated individuals and these will be compared with chronically ill patients having a more established clinical history. This allows comparison of both disease progression and the effects of drug treatment.
  • Membrane-bound and soluble proteins may be prepared from stimulated T-cells.
  • proteomic profiling of T-cells from psychosis patients and controls may be performed, providing information regarding differing expression of large and small molecular weight proteins, e.g. phosphoproteins, following stimulation.
  • Biomarker means a distinctive biological or biologically-derived indicator of a process, event, or condition. Biomarkers can be used in methods of diagnosis (e.g. clinical screening), prognosis assessment; in monitoring the results of therapy, identifying patients most likely to respond to a particular therapeutic treatment, drug screening and development.
  • the biomarker is a gene, mRNA, a protein or peptide, lipid, or metabolite.
  • the terms protein and peptide are used interchangeably herein.
  • the biomarker may be quantified. Biomarkers and uses thereof are valuable for identification of new drug treatments and for discovery of new targets for drug treatment.
  • Quantifying the amount of the biomarker present in a sample may include determining the concentration of the peptide biomarker present in the sample. Detecting and/or quantifying may be performed directly on the sample, or indirectly on an extract therefrom, or on a dilution thereof. Detecting and/or quantifying can be performed by any method suitable to identify the presence and/or amount of a specific protein in a biological sample.
  • the control sample comprises a normal control sample.
  • control sample comprises a psychotic disorder control sample.
  • method may also comprise classifying proliferative responses of a sample as having a normal profile, psychotic disorder profile, or psychotic disorder predisposition profile.
  • T-cell samples may be taken on two or more occasions from a test subject. Stimulatory responses from samples taken on two or more occasions from a test subject can be compared to identify differences between the stimulatory responses in samples taken on different occasions. Methods may include analysis of stimulatory responses from biological samples taken on two or more occasions from a test subject to quantify the level of one or more biomarkers present in the biological samples, and comparing the level of the one or more biomarkers present in samples taken on two or more occasions.
  • Diagnostic and monitoring methods of the invention are useful in methods of assessing prognosis of a psychotic disorder, in methods of monitoring efficacy of an administered therapeutic substance in a subject having, suspected of having, or of being predisposed to, a psychotic disorder and in methods of identifying an antipsychotic or pro-psychotic substance.
  • Such methods may comprise comparing the level of the one or more biomarkers in a test biological sample taken from a test subject with the level present in one or more samples taken from the test subject prior to administration of the substance, and/or one or more samples taken from the test subject at an earlier stage during treatment with the substance. Additionally, these methods may comprise detecting a change in the level of the one or more biomarkers in biological samples taken from a test subject on two or more occasions.
  • a method of diagnosis of or monitoring according to the invention may comprise quantifying the one or more biomarkers in a test biological sample taken from a test subject and comparing the level of the one or more biomarkers present in said test sample with one or more controls.
  • the control can be selected from a normal control and/or a psychotic disorder control.
  • the control used in a method of the invention can be selected from: the level of biomarker found in a normal control sample from a normal subject, a normal biomarker level; a normal biomarker range, the level in a sample from a subject with a schizophrenic disorder, bipolar disorder, related psychotic disorder, or a diagnosed predisposition thereto; a schizophrenic disorder marker level, a bipolar disorder marker level, a related psychotic disorder marker level, a schizophrenic disorder marker range, a bipolar disorder marker range and a related psychotic disorder marker range. Detecting differences in responses enables identification of biomarkers for a psychotic disorder.
  • the response may be assessed by any suitable method or combination of methods, for example by considering gene expression, at the mRNA and/or protein level, to detect differential gene expression between disorder and control samples, by considering protein levels (e.g. in cell lysate), lipid profile and/or metabolite profile.
  • the differences may manifest as the presence or absence of a biomarker or a difference (increase or decrease) in level of a biomarker, or in ratios of a biomarker or biomarkers.
  • Differences in gene expression can be detected by a modulation in mRNA or protein levels.
  • the expression of the gene present in the disorder sample may be modulated compared to the expression of the gene in the control sample, thus different levels of mRNA transcribed from the gene will be detected.
  • the expression may be increased or decreased, or different splice variants or ratios of splice variants of the mRNA may be detected.
  • the biomarker is a protein and the level of the protein present in the sample differs from the level of the protein present in the control sample.
  • the level may be modulated so that it is increased or decreased, or a difference in protein cleavage products may be found; this may be assessed by a quantitative method or determined by the presence or absence of the protein.
  • the level or ratio of one or more biomarkers is detected.
  • a sensor e.g. a biosensor comprising one or more enzymes, binding, receptor or transporter proteins, antibody, synthetic receptors or other selective binding molecules for direct or indirect detection of the biomarkers.
  • the sensor may be coupled to an electrical, optical, acoustic, magnetic or thermal transducer.
  • antibody as used in this embodiment includes, but is not limited to, polyclonal, monoclonal, bispecific, humanised or chimeric antibodies, single chain antibodies, Fab fragments and F (ab') 2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.
  • antibody as used herein also refers to immunoglobulin molecules and immunologically-active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that specifically binds an antigen.
  • the immunoglobulin molecules of the invention can be of any class (e. g., IgG, IgE, IgM, IgD and IgA) or subclass of immunoglobulin molecule.
  • Biomarkers identified using a method of the invention can be used as biomarkers for a psychotic disorder or predisposition thereto. They are thus useful in methods for monitoring or diagnosing psychotic disease.
  • the present invention may be used identify a potential therapeutic agent for the prevention, treatment or amelioration of a psychotic disorder.
  • the invention comprises comparing a response to stimulation with a response in a control sample.
  • responses in test and normal control T- cell samples exposed to a candidate therapeutic agent may be compared, identifying the candidate as a potential therapeutic agent if one or more responses in the test T- cell sample are modulated such that a normal response is restored.
  • a candidate therapeutic agent is identified if the candidate therapeutic agent is capable of modulating a response in T-cells from a subject having a psychotic disorder, in particular such that one or more responses are restored to the response characteristic of T-cells from normal individuals.
  • the response is proliferation or modulation of gene expression, i.e. changes in mRNA or protein levels.
  • the response can be assessed using the methods described herein, in particular by assessing biomarkers of response identified as described herein. Changes in proliferation can be assessed by comparing the proliferation of T-cells in the presence and absence of the candidate therapeutic agent.
  • Modulation of expression of one or more genes can be assessed by comparing the expression level of the gene or genes (at the mRNA or protein level) in the presence and absence of the candidate therapeutic agent. Modulation of protein levels can be assessed by comparing the level of the protein or proteins in the presence and absence of the candidate therapeutic agent.
  • Other suitable biomarkers of response include lipids and metabolites found at different levels in disorder and normal control samples.
  • the invention relates to a diagnostic kit or monitoring kit suitable for performing a method described herein.
  • Kits according to the invention may comprise one or more components selected from: instructions for use of the kit, one or more normal and/or psychotic disorder controls, a sensor or biosensor suitable and/or adapted for detecting a biomarker according to the invention and a ligand, e.g. nucleic acid, antibody, aptamer, or the like, capable of specifically binding a biomarker according to the invention or specifically binding a substance derived from the biomarker or from the action of the biomarker.
  • the ligand may be provided immobilised on a solid support such as bead or surface, for example in the form of an array adapted for use in a method of the invention.
  • the study was conducted in order to investigate mechanisms underlying lower proliferative responses of schizophrenia patient T-cells to stimulation with anti- CD3, by looking at activation subtype of T-cells from schizophrenia patients and controls.
  • the study was conducted as follows:
  • T-cells from schizophrenia patients and healthy controls were cultured in the presence or absence of anti-CD3 (clone OKT3) in RPMI-1640 medium supplemented with 1% GPS and 10% foetal bovine serum.
  • CD45 expression was assessed by flow cytometry.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de diagnostic ou de surveillance de la schizophrénie ou d'un trouble dépressif majeur, ou d'une prédisposition à ceux-ci. Ce procédé comprend la détection et/ou la quantification de l'expression d'une isoforme de CD45 comme biomarqueur dans un échantillon prélevé sur un sujet à tester.
PCT/GB2008/000826 2007-03-08 2008-03-10 Diagnostic de troubles psychotiques Ceased WO2008107699A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0704513A GB0704513D0 (en) 2007-03-08 2007-03-08 Diagnosing psychotic disorders
GB0704513.1 2007-03-08
GB0720545A GB0720545D0 (en) 2007-10-19 2007-10-19 Diagnosing physchotic disorders
GB0720545.3 2007-10-19

Publications (1)

Publication Number Publication Date
WO2008107699A1 true WO2008107699A1 (fr) 2008-09-12

Family

ID=39561864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/000826 Ceased WO2008107699A1 (fr) 2007-03-08 2008-03-10 Diagnostic de troubles psychotiques

Country Status (1)

Country Link
WO (1) WO2008107699A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011101666A1 (fr) 2010-02-16 2011-08-25 Loxbridge Research Llp Procédé de détection d'analyte à base d'oligonucléotide
WO2011121362A2 (fr) 2010-04-01 2011-10-06 Cambridge Enterprise Limited Marqueurs biologiques

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137108A1 (en) * 2000-11-08 2002-09-26 Michael Mullan CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker in alzheimer's disease
JP2003235557A (ja) * 2002-02-14 2003-08-26 Univ Niigata 精神分裂病により発現量が変化する遺伝子を規定する核酸を解析する方法
US20050043373A1 (en) * 2000-08-09 2005-02-24 Aventis Pharma Deutschland Gmbh Substituted an unsubstituted benzooxathiazoles and compounds derived therefrom

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043373A1 (en) * 2000-08-09 2005-02-24 Aventis Pharma Deutschland Gmbh Substituted an unsubstituted benzooxathiazoles and compounds derived therefrom
US20020137108A1 (en) * 2000-11-08 2002-09-26 Michael Mullan CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker in alzheimer's disease
JP2003235557A (ja) * 2002-02-14 2003-08-26 Univ Niigata 精神分裂病により発現量が変化する遺伝子を規定する核酸を解析する方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAZZULLO C.L. ET AL.: "Increased levels of CD8+ and CD4+45RA+ lymphocytes in schizophrenic patients", SCHIZOPHRENIA RES., vol. 31, no. 1, 4 May 1998 (1998-05-04), pages 49 - 55, XP009102689 *
CRADDOCK R.M. ET AL.: "Altered T-cell function in schizophrenia: a cellular model to investigate molecular disease mechanisms", PLOS ONE, vol. 2, no. 8, 1 August 2007 (2007-08-01), pages E692, XP002486995 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011101666A1 (fr) 2010-02-16 2011-08-25 Loxbridge Research Llp Procédé de détection d'analyte à base d'oligonucléotide
WO2011121362A2 (fr) 2010-04-01 2011-10-06 Cambridge Enterprise Limited Marqueurs biologiques
WO2011121362A3 (fr) * 2010-04-01 2011-11-24 Cambridge Enterprise Limited Marqueurs biologiques

Similar Documents

Publication Publication Date Title
JP6711754B2 (ja) アルツハイマー病および他の神経変性障害のためのバイオマーカーおよび診断方法
EP2656080B1 (fr) Biomarqueurs pour le diagnostic de la schizophrénie
JP2020500309A (ja) エキソソームの亜集団の定量および神経変性障害の診断
JP2014521315A (ja) アルツハイマー病の診断
EP3452830B1 (fr) Dosage pour le diagnostic d'une maladie neurologique
WO2010005387A1 (fr) Procédé et marqueurs inédits pour le diagnostic de la sclérose en plaques
US20120094858A1 (en) Biomarkers
CA2790094A1 (fr) Biomarqueurs
WO2016113570A1 (fr) Panels de biomarqueurs de sérum pour un trouble bipolaire
WO2011121362A2 (fr) Marqueurs biologiques
WO2011092504A2 (fr) Marqueurs biologiques
JP2009517073A (ja) 精神病性障害用のバイオマーカーをモニタリング、診断及び同定する方法
WO2008107699A1 (fr) Diagnostic de troubles psychotiques
WO2010064030A1 (fr) Biomarqueurs
WO2008107701A1 (fr) Diagnostic de troubles psychotiques
CN116235054A (zh) 确定受试者由轻中度covid-19病程到重或危重病程的倾向性的方法
WO2008107700A1 (fr) Diagnostic de troubles psychotiques
US10317401B2 (en) Methods and compositions for the prediction and treatment of focal segmental glomerulosclerosis
US20230146841A1 (en) Tnfaip3 as a biomarker for autoimmune diseases
Endpoint 26 Biomarkers of Kidney Injury and Rejection
KR20250163550A (ko) 자폐증 진단 및 치료용 조성물
US9784739B2 (en) Regulatory brain specific cytoplasmic RNAS (BC RNAs) and methods of use thereof in diagnosis and treatment of neuropsychiatric lupus
HK40083580A (en) Protein markers for assessing alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08718672

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08718672

Country of ref document: EP

Kind code of ref document: A1